Administer HZN-825 once daily (QD) or twice daily (BID)

2 trials

Sponsors

Sato Toshiyuki, Sakanishi Ryuichi

Conditions

Diffuse Cutaneous Systemic SclerosisIdiopathic pulmonary fibrosis (IPF)

Phase 2

A Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis

Active, not recruitingJPRN-jRCT2031220221

Sato ToshiyukiDiffuse Cutaneous Systemic Sclerosis

Start: 2022-07-18Target: 21Updated: 2026-06-29

A Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial of HZN-825 in Patients with Idiopathic Pulmonary Fibrosis

Active, not recruitingJPRN-jRCT2031220586

Sakanishi RyuichiIdiopathic pulmonary fibrosis (IPF)

Start: 2023-01-11Target: 16Updated: 2026-06-29